Evidence map›Paper›PMID 28646699›Full record

ReviewDiabetes research and clinical practice2017

Insulin and the polycystic ovary syndrome.

Djuro Macut, Jelica Bjekić-Macut, Dario Rahelić, Mirjana Doknić

2 registry-linked trialsAbstract readReview
PubMed Publisher
In one paragraph

Review in Diabetes research and clinical practice, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT03151005. Cited by 113 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
113citing papers in PubMed, 5 pooled it
20.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03151005 phase4completed

Randomized Clinical Trial to Evaluate The Effect of Metformin-GLP-1 Receptor Agonist Versus Oral Contraceptive (OC) Therapy on Reproductive Disorders and Cardiovascular Risks in Overweight Polycystic Ovarian Syndrome (PCOS) Patients

Ran2017Enrolled70Registered outcomes5Posted comparisons0ConditionsObesity, Overweight, Polycystic Ovary Syndrome (PCOS)ArmsMetformin-GLP-1 Receptor Agonist, Metformin-Oral Contraceptive(OC)
PMID 28860713PMID 24389146PMID 30459598PMID 12046553PMID 28463030PMID 26426951PMID 22777527PMID 20471009PMID 29569621PMID 14688154other papers from this trial
Open the trial in the graph
NCT04836910 not yet recruitingnot on this mapstarted 2025, after this paper: background citation

The Change in Microbiome Following Treatment of Women With Polycystic Ovaries

TypeobservationalSponsorSheba Medical CenterRan2025 to 2027Enrolled40ConditionsPolycystic Ovary Syndrome, Microbial ColonizationArmsDietary recommendations, Oral contraceptive pills, Metformin
3 · Its place in the literature

Who cites it

113 citing papers in PubMed, 5 syntheses or guidelines pooled it, 265 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Article
  11. Article
  12. Review
  13. Observational
  14. Review
  15. The Effect of Supplementation withJournal of research in pharmacy practice · 2026
    Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review

53 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Djuro MacutClinic of Endocrinology, Diabetes and Metabolic Diseases, Faculty of Medicine, University of Belgrade, Belgrade, Serbia. Electronic address: djmacut@gmail.com.
Jelica Bjekić-MacutDepartment of Endocrinology, UMC Bežanijska kosa, Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
Dario RahelićDepartment of Endocrinology, Diabetes and Clinical Pharmacology, Clinic for Internal Medicine, School of Medicine Zagreb, Dubrava University Hospital, Zagreb, Croatia.
Mirjana DoknićClinic of Endocrinology, Diabetes and Metabolic Diseases, Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
University of Belgrade · RSUniversity Hospital Dubrava · HR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Polycystic ovary syndrome (PCOS) is the most prevalent endocrinopathy among women during reproductive age. PCOS is characterised by hyperandrogenaemia, hyperinsulinaemia, and deranged adipokines secretion from the adipose tissue. In addition to the reduced insulin sensitivity, PCOS women exhibit β-cell dysfunction as well. Low birth weight and foetal exposure to androgens may contribute to the development of the PCOS phenotype during life. Further metabolic complications lead to dyslipidaemia, worsening obesity and glucose tolerance, high prevalence of metabolic syndrome, and greater susceptibility to diabetes. PCOS women show age-related existence of hypertension, and subtle endothelial and vascular changes. Adverse reproductive outcomes include anovulatory infertility, and unrecognised potentiation of the hormone-dependent endometrial cancer. The main therapeutic approach is lifestyle modification. Metformin is the primary insulin-sensitising drug to be used as an adjuvant therapy to lifestyle modification in patients with insulin resistance and impaired glucose tolerance, as well as in those referred to infertility treatment. Thiazolidinediones should be reserved for women intolerant of or refractory to metformin, while glucagon-like peptide 1 analogues has a potential therapeutic use in obese PCOS women. Randomised clinical trials and repetitive studies on different PCOS phenotypes for the preventive actions and therapeutic options are still lacking, though.

Indexed as

FemaleHumansHypoglycemic AgentsInsulinInsulin ResistanceMetforminPolycystic Ovary SyndromeHypoglycemic AgentsInsulinMetforminAndrogensInsulinInsulin resistanceMetforminPolycystic ovary syndrome

Identifiers

PMID28646699
OpenAlexW2625244462

What Socratic holds

Texttitle and abstract
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.